FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385381818> ?p ?o ?g. }

• W4385381818 endingPage "1398" @default.
• W4385381818 startingPage "1388" @default.
• W4385381818 abstract "ABSTRACT Background Tourette syndrome (TS) is a neurodevelopmental disorder characterized by motor and phonic tics. Objective To assess the safety and efficacy of deutetrabenazine (Teva Neuroscience, Inc, Parsippany, NJ), a vesicular monoamine transporter 2 inhibitor, in children and adolescents with TS. Methods Alternatives for Reducing Tics in TS (ARTISTS) open‐label extension (OLE) (NCT03567291) was a 54‐week, global, phase 3, open‐label extension study of deutetrabenazine (6–48 mg daily) conducted May 28, 2018 to April 3, 2020 with a 2‐week randomized withdrawal period. Participants (6–16 years of age) had TS and active tics causing distress or impairment. Safety (primary outcome) was assessed by treatment‐emergent adverse events (TEAEs) and clinical laboratory testing. Efficacy was measured by the Yale Global Tic Severity Scale‐Total Tic Score (YGTSS‐TTS). Results The intent‐to‐treat population (228 participants; mean age, 12.0 years; 79.8% male; 86.4% white) had a median (range) duration of exposure of 28.4 (0.3–52.9) weeks. Of 227 participants in the safety analysis, 161 (70.9%) reported ≥1 TEAE (exposure‐adjusted incidence rate, 2.77/patient‐year), of which 95 (41.9%) were treatment related. The most frequently reported TEAEs were headaches, somnolence, nasopharyngitis, weight increases, and anxiety. No additional safety signals were observed. Worsening of YGTSS‐TTS after the 2‐week randomized withdrawal was not statistically significant (least squares mean difference, −0.4; P = 0.78). Several exploratory measures showed sustained improvement throughout the treatment periods. Conclusions In this long‐term, open‐label trial, deutetrabenazine was well tolerated with low frequency of TEAEs. There was no significant difference in tics between treatment arms during the 2‐week randomized withdrawal period, however, descriptive statistics and comparison with baseline showed a numeric improvement in tics, quality of life, and other measures." @default.
• W4385381818 created "2023-07-30" @default.
• W4385381818 creator A5008039287 @default.
• W4385381818 creator A5020080352 @default.
• W4385381818 creator A5024659043 @default.
• W4385381818 creator A5030504669 @default.
• W4385381818 creator A5033328565 @default.
• W4385381818 creator A5048908807 @default.
• W4385381818 creator A5051528792 @default.
• W4385381818 creator A5053278061 @default.
• W4385381818 creator A5061963566 @default.
• W4385381818 creator A5064135529 @default.
• W4385381818 creator A5068655451 @default.
• W4385381818 creator A5073573130 @default.
• W4385381818 creator A5081672652 @default.
• W4385381818 date "2023-08-24" @default.
• W4385381818 modified "2023-10-17" @default.
• W4385381818 title "Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study" @default.
• W4385381818 cites W1981277671 @default.
• W4385381818 cites W2019101336 @default.
• W4385381818 cites W2107832644 @default.
• W4385381818 cites W2108710427 @default.
• W4385381818 cites W2139693994 @default.
• W4385381818 cites W2310364843 @default.
• W4385381818 cites W2475146005 @default.
• W4385381818 cites W2562054892 @default.
• W4385381818 cites W2583683075 @default.
• W4385381818 cites W2783378259 @default.
• W4385381818 cites W2806967531 @default.
• W4385381818 cites W2809637835 @default.
• W4385381818 cites W2920938584 @default.
• W4385381818 cites W2943985522 @default.
• W4385381818 cites W2944778893 @default.
• W4385381818 cites W2949172543 @default.
• W4385381818 cites W2952673344 @default.
• W4385381818 cites W2998758411 @default.
• W4385381818 cites W3008830024 @default.
• W4385381818 cites W3082412772 @default.
• W4385381818 cites W3133862715 @default.
• W4385381818 cites W3204636898 @default.
• W4385381818 cites W3206336443 @default.
• W4385381818 cites W4213288886 @default.
• W4385381818 cites W4380224969 @default.
• W4385381818 doi "https://doi.org/10.1002/mdc3.13849" @default.
• W4385381818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37772282" @default.
• W4385381818 hasPublicationYear "2023" @default.
• W4385381818 type Work @default.
• W4385381818 citedByCount "0" @default.
• W4385381818 crossrefType "journal-article" @default.
• W4385381818 hasAuthorship W4385381818A5008039287 @default.
• W4385381818 hasAuthorship W4385381818A5020080352 @default.
• W4385381818 hasAuthorship W4385381818A5024659043 @default.
• W4385381818 hasAuthorship W4385381818A5030504669 @default.
• W4385381818 hasAuthorship W4385381818A5033328565 @default.
• W4385381818 hasAuthorship W4385381818A5048908807 @default.
• W4385381818 hasAuthorship W4385381818A5051528792 @default.
• W4385381818 hasAuthorship W4385381818A5053278061 @default.
• W4385381818 hasAuthorship W4385381818A5061963566 @default.
• W4385381818 hasAuthorship W4385381818A5064135529 @default.
• W4385381818 hasAuthorship W4385381818A5068655451 @default.
• W4385381818 hasAuthorship W4385381818A5073573130 @default.
• W4385381818 hasAuthorship W4385381818A5081672652 @default.
• W4385381818 hasBestOaLocation W43853818181 @default.
• W4385381818 hasConcept C118552586 @default.
• W4385381818 hasConcept C126322002 @default.
• W4385381818 hasConcept C139265228 @default.
• W4385381818 hasConcept C15744967 @default.
• W4385381818 hasConcept C168563851 @default.
• W4385381818 hasConcept C187212893 @default.
• W4385381818 hasConcept C197934379 @default.
• W4385381818 hasConcept C2777026814 @default.
• W4385381818 hasConcept C2777200579 @default.
• W4385381818 hasConcept C2778541695 @default.
• W4385381818 hasConcept C2779034229 @default.
• W4385381818 hasConcept C2908647359 @default.
• W4385381818 hasConcept C70410870 @default.
• W4385381818 hasConcept C71924100 @default.
• W4385381818 hasConcept C99454951 @default.
• W4385381818 hasConceptScore W4385381818C118552586 @default.
• W4385381818 hasConceptScore W4385381818C126322002 @default.
• W4385381818 hasConceptScore W4385381818C139265228 @default.
• W4385381818 hasConceptScore W4385381818C15744967 @default.
• W4385381818 hasConceptScore W4385381818C168563851 @default.
• W4385381818 hasConceptScore W4385381818C187212893 @default.
• W4385381818 hasConceptScore W4385381818C197934379 @default.
• W4385381818 hasConceptScore W4385381818C2777026814 @default.
• W4385381818 hasConceptScore W4385381818C2777200579 @default.
• W4385381818 hasConceptScore W4385381818C2778541695 @default.
• W4385381818 hasConceptScore W4385381818C2779034229 @default.
• W4385381818 hasConceptScore W4385381818C2908647359 @default.
• W4385381818 hasConceptScore W4385381818C70410870 @default.
• W4385381818 hasConceptScore W4385381818C71924100 @default.
• W4385381818 hasConceptScore W4385381818C99454951 @default.
• W4385381818 hasIssue "9" @default.
• W4385381818 hasLocation W43853818181 @default.
• W4385381818 hasLocation W43853818182 @default.
• W4385381818 hasOpenAccess W4385381818 @default.
• W4385381818 hasPrimaryLocation W43853818181 @default.

• next